Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) insider Adam C. Vandervoort sold 11,011 shares of the stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $8.42, for a total transaction of $92,712.62. Following the sale, the insider now directly owns 64,308 shares in the company, valued at approximately $541,473.36. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Teladoc Health Stock Up 3.1 %
Shares of NYSE TDOC opened at $8.43 on Friday. The company has a 50 day simple moving average of $10.42 and a 200-day simple moving average of $9.75. The company has a market capitalization of $1.46 billion, a P/E ratio of -1.46 and a beta of 1.27. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.73 and a quick ratio of 1.69. Teladoc Health, Inc. has a 1 year low of $6.76 and a 1 year high of $15.43.
Teladoc Health (NYSE:TDOC – Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The health services provider reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). The company had revenue of $640.49 million for the quarter, compared to analysts’ expectations of $639.44 million. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. On average, equities research analysts predict that Teladoc Health, Inc. will post -1.16 earnings per share for the current year.
Hedge Funds Weigh In On Teladoc Health
Analysts Set New Price Targets
Several research firms have recently issued reports on TDOC. Piper Sandler lowered their target price on shares of Teladoc Health from $13.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. Oppenheimer decreased their price target on shares of Teladoc Health from $14.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday, January 24th. The Goldman Sachs Group decreased their price target on shares of Teladoc Health from $16.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Bank of America raised their price target on shares of Teladoc Health from $11.50 to $13.50 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research note on Thursday, February 27th. Eleven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $11.26.
Read Our Latest Research Report on TDOC
About Teladoc Health
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Further Reading
- Five stocks we like better than Teladoc Health
- How to Calculate Return on Investment (ROI)
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Stock Market Sectors: What Are They and How Many Are There?
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Top Stocks Investing in 5G Technology
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.